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her primary care physician to the Nephrology Clinic of the
New England Medical Center 11 years ago for control of hyper-
tension. At her initial visit, her blood pressure was 190/120
mm Hg and the serum creatinine was 1.3 mg/dL. Treatment
with enalapril was begun and the patient was followed several
times per year. Seven years ago, she was enrolled in the Modifi-
cation of Diet in Renal Disease (MDRD) Study and was ran-
domly assigned to the high-protein group (estimated protein
intake, 1.1 to 1.2 g/kg/day). At enrollment, her weight was 76
kg; BUN, 30 mg/dL; and serum creatinine, 2.1 mg/dL. Six years
ago, the serum calcium was 9.7 mg/dL and phosphorus 5.4
mg/dL; calcium carbonate therapy was started. Three years
ago, the BUN had risen to 76 mg/dL, the serum creatinine to
5.4 mg/dL, and the serum albumin was 4.1 mg/dL. Four months
later, iron supplementation and erythropoietin were begun
when her hematocrit was noted to be 30%. After reading litera-CASE PRESENTATIONS
ture provided by the nephrology team on modalities of renal
Patient 1 replacement therapy, she chose peritoneal dialysis. Mild uremic
A 56-year-old man presented to the emergency room at New symptoms appeared four months later. The blood pressure
England Medical Center in May 1998 with nausea, vomiting, was 130/82 mm Hg; hematocrit, 36%; BUN, 83 mg/dL; serum
hemoptysis, pulmonary edema, and altered sensorium. A pri- creatinine, 6.9 mg/dL; albumin, 4.2 g/dL; calcium, 8.9 mg/dL;
mary care physician had seen him for hypertension and renal and phosphorus, 4.2 mg/dL. A peritoneal dialysis catheter was
insufficiency on a few occasions in the previous five years, but placed, and dialysis was initiated one month later. The patient
he was lost to follow-up in the last year. At presentation, he initially performed continuous ambulatory peritoneal dialysis
was somnolent and his blood pressure was 170/120 mm Hg. and subsequently received a cadaveric renal transplant.
Positive findings on examination included a pericardial friction
rub, diffuse pulmonary crackles, mild anasarca, and asterixis.
Laboratory tests revealed a hematocrit of 29%; blood urea DISCUSSION
nitrogen, 236 mg/dL; serum creatinine, 15.4 mg/dL; albumin,
Dr. Brian J. G. Pereira (Vice Chairman, Department3.3 g/dL; calcium, 6.3 mg/dL; and phosphorus, 7.4 mg/dL. The
arterial blood pH was 7.14; pO2, 133; pCO2, 12; and bicarbonate, of Medicine, New England Medical Center, and Professor
4 mEq/liter. He was admitted to the Intensive Care Unit (ICU), of Medicine, Tufts University School of Medicine, Boston,
where a subclavian dialysis catheter was placed and hemodialy-
Massachusetts, USA): These two cases exemplify the ex-sis started. After three days in the ICU, he was transferred to
tremes in caring for patients who are approaching end-the ward. He remained hospitalized for 15 days, during which
his cardiovascular and fluid status were stabilized, permanent stage renal disease (ESRD). The first patient essentially
access was placed, and he underwent education regarding dial- received no pre-ESRD care because he was lost to fol-
ysis and the management of uremic complications.
low-up. There is no indication that strategies for delaying
progression of renal disease were employed. Also, con-Patient 2
trol of his blood pressure was poor, and he received noA 42-year-old woman with the established diagnosis of au-
tosomal-dominant polycystic kidney disease was referred by treatment for anemia, malnutrition, or renal osteodystro-
phy. The patient was never seen by a nephrologist and
thus did not have the opportunity to make an informedThe Nephrology Forum is funded in part by grants from Amgen,
Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo- choice about the modality of renal replacement therapy.
rated; AstraZeneca LP; and R & D Laboratories. Dialysis access could not be placed in a timely manner,
and dialysis needed to be started urgently with a tempo-Key words: renal replacement therapy, dialysis, osteodystrophy, ESRD
costs and outcomes. rary catheter. The second patient’s case represents opti-
mal pre-ESRD care by current standards. 2000 by the International Society of Nephrology
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Worldwide, the number of patients with end-stage re- Consensus Statement on Morbidity and Mortality of Di-
alysis recommended that referral of a patient to anal disease receiving renal replacement therapy (RRT)
is growing. In the United States, the number of patients nephrologist should occur when the serum creatinine
level reaches 1.5 mg/dL in women and 2.0 mg/dL in menenrolled in the Medicare-funded program has grown sub-
stantially, from approximately 10,000 beneficiaries in [6]. These levels of renal function can be used to define
entry into the pre-ESRD phase. A recent analysis of the1973 to 86,354 in 1983, and to 304,083 as of December 31,
1997 [1]. These figures represent a more than doubling population-based National Health and Nutrition Exami-
nation Survey III has estimated that the number of indi-in the prevalence of ESRD during the last decade and
correspond to an annualized increase of approximately viduals in the U.S. with serum creatinine levels above
1.5 mg/dL, 1.7 mg/dL, and 2.0 mg/dL are 10.9 million,10%. The rising prevalence of treated ESRD can be
attributed primarily to the increase in the number of 3.0 million, and 0.8 million, respectively [7].
Indices of “optimal pre-ESRD care” have been nei-individuals added to the rolls of treated ESRD patients
each year. In fact, 79,102 new patients entered the U.S. ther clearly defined nor validated. This deficiency stands
in contrast to the well-established indices of “optimalESRD program in 1997 alone [1]. Patients with ESRD
consume a disproportionate share of national health care dialysis care,” such as those developed by the U.S. Health
Care Financing Administration (HCFA) Health Careresources. In 1997, the total cost of care of U.S. patients
with ESRD was estimated to be $15.62 billion [1]. De- Quality Improvement Program (ESRD Core Indicators
Project) in 1994 [8] and, more recently, the Nationalspite the magnitude of the resources committed to the
treatment of ESRD patients, these patients continue to Kidney Foundation’s Dialysis Outcomes Quality Initia-
tive Guidelines (NKF-DOQIe) [9]. The identificationexperience significant morbidity and a reduced quality
of life. Hospitalization rates for patients with ESRD of well-defined indices of optimal pre-ESRD care has
been handicapped by the paucity of studies exploring theare much higher than those for age- and risk-adjusted
comparative cohorts. In addition, the mortality rate link between measures of pre-ESRD care and outcomes
after the start of RRT. Nonetheless, several factors couldamong dialysis patients remains high. The life expectancy
of dialysis patients in the U.S. is only 16% to 37% of be used to define the quality of pre-ESRD care (Fig. 1)
[10]. I will restrict this review to selected indices of qual-the age-, gender-, and race-matched population [2].
Analyses of historical data from databases maintained ity of pre-ESRD care. For each index, I will address the
rationale for its selection as an index of quality of care,by single centers, dialysis provider “chains,” and govern-
mental organizations have demonstrated a strong associ- examine its current status in the pre-ESRD population,
and make recommendations for optimization of care.ation between the risk of death and factors such as age,
gender, race, non-renal co-morbidity, nutrition, and dose
Early detection of renal insufficiency and interventionsof dialysis [3–5]. However, despite increasing attention
for slowing the rate of progression of renal diseaseto modifiable factors, the mortality rate among ESRD
patients remains high. Hence, other factors might be Renal function progressively declines in most patients
with renal disease after sufficient damage has raised theoperative. The quality of care prior to initiation of dial-
ysis (“pre-ESRD care”) is a factor that thus far has re- serum creatinine level to 1.5 to 2.0 mg/dL. Indeed, in the
Modification of Diet in Renal Disease (MDRD) study ofceived scant attention, but which theoretically could sig-
nificantly affect morbidity and mortality in dialysis 840 patients with a variety of non-diabetic renal diseases
and an initial glomerular filtration rate (GFR) rangingpatients. A successful strategy for improving pre-ESRD
care requires: (1) establishing the limits of renal function from 13 to 55 mL/min, GFR declined in 85% of patients
and was stable in the remainder [11]. The average ratethat define “pre-ESRD”; (2) identifying indices of pre-
ESRD care, based on a demonstrated association be- of decline was 4 mL/min/year. The benefit of angiotensin-
converting-enzyme (ACE) inhibitors [12–14], blood pres-tween these indices and clinical and economic outcomes;
(3) elucidating the prevalence and predictors of subopti- sure control [15–18], and blood glucose control (among
diabetics) [19, 20] in retarding the progression of renalmal pre-ESRD care; (4) determining and correcting the
causes of suboptimal pre-ESRD care; and (5) estimating failure in patients with renal insufficiency and protein-
uria has been well established. The benefit of low-proteinthe size of the pre-ESRD population and the resources
required to provide optimal pre-ESRD care. diets is controversial [21–23], but a meta-analysis of clini-
cal trials suggests that dietary protein restriction retardsThe limits of renal function that constitute the pre-
ESRD stage and the size of the pre-ESRD population the development and progression of diabetic and nondia-
betic renal disease [24].are currently not well established. While pre-ESRD un-
questionably ends with the initiation of RRT, the renal Limited information is available in the U.S. regarding
early detection of renal disease and interventions to de-function at which a patient with chronic renal failure
(CRF) could be classified as pre-ESRD has not been lay its progression. McClellan et al conducted a retro-
spective chart review of 587 Medicare patients admittedagreed upon. A 1994 National Institutes of Health (NIH)
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Fig. 1. Components of optimal pre-end-stage renal disease (ESRD) care. Abbreviations are: CRF, chronic renal failure; RRT, renal replacement
therapy; ACE, angiotensin-converting enzyme; BP, blood pressure [32].
Table 1. Early detection of renal disease and use of interventions to delay its progression in the population at risk for chronic renal failurea
Diabetes mellitus Hypertension
% %
Tests for evidence of renal disease
Microalbuminuria 1.6 0.6
Urinalysis 68 58
Serum creatinine 91 97
Renal disease documented in the discharge summary among patients with
Proteinuria $11 7.8 12.5
Serum creatinine $1.5 mg/dL 9.8 11.4
ACE inhibitors prescribed at discharge among patients with
Proteinuria $11 33.3 12.5
Serum creatinine $1.5 mg/dL 31.7 25.7
Nonsteroidal anti-inflammatory drugs prescribed at discharge 6.0 8.8
a Adapted from Ref. 24. Data comprise a retrospective chart review of 587 Medicare patients younger than 75 years
to the hospital with a primary diagnosis of diabetes melli- Prevention or attenuation of uremic complications
tus or hypertension in the state of Georgia [25]. The Hypoalbuminemia. Hypoalbuminemia at initiation of
salient findings of this study were that: (1) testing for dialysis is a strong predictor of early death on dialysis.
renal disease among individuals at high risk for renal Studies involving U.S. and Canadian patients have re-
disease was not universal; (2) medical records of patients vealed a strong association of low serum albumin level
with abnormal renal function tests documented neither at the start of dialysis with subsequent increased risk of
awareness of the condition nor plans for further evalua- death on dialysis (Fig. 2) [27, 28]. These results are not
tion of the possible underlying renal disease; (3) strate- surprising, as several studies have shown that hypoal-
gies for delaying progression were infrequently employed; buminemia is an important predictor of mortality among
and (4) nephrotoxic medications such as nonsteroidal anti- patients who are already undergoing dialysis [29]. Hypo-
inflammatory drugs continued to be prescribed to pa- albuminemia also has been associated with increased
tients with abnormal renal function (Table 1). The results rates of hospitalization among patients with ESRD [30].
of this study probably reflect widespread suboptimal clin- Hypoalbuminemia among patients with CRF accrues
ical practice and are consistent with a survey of physi- from multiple causes [31, 32]. Declining renal function
cians’ “self-reported behaviors,” which revealed limited is associated with multiple derangements in protein me-
awareness of and compliance with published guidelines tabolism and spontaneous dietary protein restriction due
to loss of appetite. These alterations lead to loss of leanfor the care of patients with diabetes [26].
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years, female, non-white, diabetic, covered by non-pri-
vate insurance or uninsured, unemployed, starting hemo-
dialysis (as opposed to peritoneal dialysis), and treated
in certain geographic regions. Similarly, in a recent study
of patients who began hemodialysis at the New England
Medical Center, Boston, between 1992 and 1997, the
adjusted odds of having hypoalbuminemia were greater
among African-Americans, patients with diabetic ne-
phropathy, and patients whose predicted GFR was less
than 5 mL/min/1.73 m2 at the initiation of dialysis [37].
This association between hypoalbuminemia and demo-
graphic, socioeconomic, and geographic factors suggestsFig. 2. Malnutrition at the start of dialysis is associated with increased
mortality. Based on data from the Case-Mix Adequacy Study of the that differences in access to care and practice patterns
United States Renal Data System, which included 2897 hemodialysis contribute to the high prevalence of hypoalbuminemia(h) and 666 peritoneal dialysis ( ) patients who began dialysis in
among patients beginning dialysis.1986–87 [27].
Practice patterns in the U.S., which are potentially
modifiable, could affect the high prevalence of malnutri-
tion in patients beginning dialysis. First, patients who
are referred late to a nephrologist are more likely to
present with hypoalbuminemia at the start of dialysis
than are patients referred earlier [37]. Whether a differ-
ence exists in long-term outcomes between patients re-
ferred early versus late is not yet known. Second, an
analysis of the Dialysis Morbidity and Mortality Study
(DMMS) Wave 2 demonstrated that only one-half of
the patients who began dialysis were evaluated by a
trained dietitian during the pre-ESRD phase of CRF [2].
Adequate pre-ESRD nutritional care, as recommended
in the 1993 NIH Consensus Statement, involves an early
nutritional assessment by a trained dietitian; specific di-Fig. 3. Serum albumin levels at initiation of dialysis. Based on data
from 110,843 patients who began dialysis in the United States between etary recommendations for protein, energy, carbohy-
1995 and 1997 [36]. Mean, 3.2 g/dL; median, 3.3 g/dL. drate, lipid, fluid, and sodium and phosphate intake; and
continued monitoring of nutritional and fluid status [6].
A protein intake of 0.7 to 0.8 g/kg/day, the minimum
required dietary allowance for adults, is recommendedbody mass and to increased essential amino acid and
unless malnutrition is present, when protein intakenitrogen requirements. Decreased production of albu-
should be 1.0 to 1.2 g/kg/day. Urinary urea nitrogenmin due to liver dysfunction, excessive losses due to
appearance can be calculated to estimate protein cata-nephrotic syndrome, or fluid shifts between the intracel-
bolic rate and to monitor protein intake [38].lular and the extracellular compartments also can influ-
These considerations notwithstanding, hypoalbumi-ence serum albumin levels. Finally, acute and chronic
nemia in CRF might not merely reflect inadequate pro-inflammatory states (perhaps including CRF) can mark-
tein intake and consequently might not be corrected byedly influence the serum albumin concentration [33, 34].
nutritional intervention alone [34]. Malnutrition, cardio-The prevalence of pre-ESRD hypoalbuminemia is
vascular disease, and inflammation can be linked in thehigh among patients beginning RRT in the U.S. The U.S.
pathogenesis of hypoalbuminemia. Research is neededRenal Data System Case Mix Severity Study reported a
to: (1) further elucidate the mechanism of hypoalbumi-50% prevalence of hypoalbuminemia among patients
nemia in patients with CRF; (2) determine whether pre-who began dialysis in the U.S. in 1986 and 1987 [35].
ESRD dietary intervention improves serum albumin;We recently examined the prevalence of, and factors
and (3) evaluate whether improved serum albumin isassociated with, hypoalbuminemia at initiation of dialysis
associated with improved outcomes in patients withamong patients who began dialysis in the U.S. between
ESRD. Meanwhile, timely use of interventions such as1995 and 1997 [36]. The serum albumin was below the
modification of cardiovascular risk factors, adequaterecorded lower limit of normal in 60% and # 3.5 g/dL
control of diabetes, and optimal control of uremic com-in 67% (Fig. 3). The odds of having hypoalbuminemia
were higher among patients who were older than 65 plications could ameliorate co-morbid conditions and
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potentially reduce the prevalence of hypoalbuminemia
prior to the initiation of RRT.
Severe anemia. Several issues regarding the manage-
ment of anemia in pre-dialysis patients require clarifica-
tion. These include determining the following: (1) long-
term effect of correction of anemia with recombinant
human erythropoietin (rHuEPO), including the effect
of partial regression of left-ventricular hypertrophy
(LVH) on the frequency of cardiac complications; (2)
optimal hematocrit level; (3) appropriate patient selec-
tion for rHuEPO therapy; (4) cost-effective rHuEPO
dosing strategies; and (5) clinical predictors of develop-
ment or exacerbation of hypertension.
Heart disease is the leading cause of death among
patients with ESRD. Left-ventricular hypertrophy, pres-
ent in as many as 74% of patients at initiation of RRT,
and cardiac failure are important predictors of cardiac
morbidity and mortality among patients undergoing dial-
ysis [39, 40]. Foley and colleagues reported that among
patients with a left-ventricular mass greater than the
mean for the study population at initiation of dialysis,
the mortality rate was higher than that in patients with
a left-ventricular mass below the mean (Fig. 4A) [41].
Patients with cardiac failure at the initiation of dialysis
had a 79% higher relative risk of mortality compared
with patients without cardiac failure (Fig. 4B). Anemia is
independently associated with the development of LVH
and other cardiac complications among patients with
CRF [40, 42]. Treatment of anemia with rHuEPO results
in partial regression of LVH, both among dialysis and
pre-ESRD patients [43]. Further, rHuEPO has reduced
Fig. 4. (A) Predicted survival (Cox proportional hazards) for patientsthe frequency of cardiac complications such as CHF and
at initiation of dialysis with left-ventricular mass index above and belowthe number of days of hospitalization among dialysis the gender-adjusted mean (reprinted with permission [41]). (B) Esti-
patients [44]. mated survival (Cox proportional hazards) for patients at initiation of
dialysis with and without cardiac failure at baseline (reprinted withWe recently examined hematocrit levels immediately
permission [41]).prior to initiation of chronic dialysis among patients who
began dialysis between 1995 and 1997 in the United
States and found that 51% of patients had a pre-dialysis
hematocrit of ,28% (Fig. 5) [36]. The odds of having a declines below 80% of the mean level for the gender- and
age-matched population [45]. Oral iron supplementationhematocrit ,28% at the initiation of dialysis were higher
among females, non-whites, those covered by non-private and correction of nutritional deficiencies are appropriate
initial steps; worsening of anemia should prompt rHuEPOinsurance or uninsured patients, and those whose initial
modality was hemodialysis (as opposed to peritoneal therapy. The hematocrit threshold at which rHuEPO ther-
apy should be started in pre-ESRD patients and thedialysis). Overall, only 23% of patients had received
rHuEPO prior to initiation of dialysis. The association ideal maintenance level have not been established. A
hematocrit level under 30% clearly justifies rHuEPObetween anemia and demographic and socioeconomic
factors, and the low prevalence of rHuEPO use suggest therapy. The DOQI recommendation of a target hema-
tocrit of 33% to 36% for patients on dialysis [45] appearsthat differences in access to care and practice patterns
contribute to the high prevalence of anemia among pa- appealing. However, the efficacy and safety of this target
have not been established. The recommendation oftients beginning RRT. Whether anemia prior to initia-
tion of dialysis is associated with an increased mortality transferrin saturation .20% and ferritin .100 ng/ml for
dialysis patients could be applied to pre-ESRD patients,rate remains to be established.
Patients with CRF should be monitored regularly for as adequate iron stores are necessary to sustain erythro-
poiesis in response to rHuEPO.declining hematocrit, and a thorough investigation for
non-renal causes of anemia is warranted if the hematocrit Concerns have been raised regarding the safety of pre-
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Fig. 5. Hematocrit levels at initiation of dial-
ysis. Based on data from 131,484 patients who
began dialysis in the United States between
1995 and 1997 [36]. Mean, 27.9%; median,
27.9%.
ESRD rHuEPO therapy, specifically, the risk of worsen- critical. Hyperphosphatemia and hypocalcemia must be
ing hypertension and accelerated deterioration of renal corrected by modifying the diet, utilizing phosphate
function. Treatment with rHuEPO can elevate blood binders, and administering calcitriol. Dietary phospho-
pressure or require an increase in antihypertensive medi- rus should be restricted at the earliest manifestations of
cation [46]. However, clinical trials have shown that renal azotemia, at the latest before the creatinine clearance
failure does not progress when blood pressure control falls below 40 mL/min, without awaiting the develop-
is maintained during rHuEPO therapy [47]. Another ment of hyperphosphatemia [49, 54, 55]. Therapy with
important consideration regarding the widespread use calcium-containing phosphate binders should be initi-
of pre-ESRD rHuEPO therapy is its cost [48]. The addi- ated when dietary manipulation alone is insufficient to
tion of pre-dialysis patients to the pool of those receiving maintain the serum phosphate at a normal level. Alumi-
rHuEPO therapy might significantly raise total health num-containing binders should be reserved for extreme
care costs. Consequently, policies aimed at maximizing hyperphosphatemia despite calcium and calcitriol ther-
the cost-effectiveness of this therapy are needed. apy, or if hypercalcemia is present. There is little experi-
Renal osteodystrophy. Reduced renal function is asso- ence with the newer calcium-free phosphate binders, but
ciated with a variety of bone disorders including osteitis these agents are likely to be useful in the management
fibrosa (the hallmark lesion of secondary hyperparathy- of such patients.
roidism), osteomalacia (due to vitamin D deficiency or The use of vitamin D supplements during the pre-
excess aluminum), aplastic bone disease (excess alumi- ESRD phase is controversial because of concerns that
num or oversuppression of parathyroid hormone pro- progression of renal disease will be hastened [56].
duction with calcitriol), or mild and mixed lesions [49]. Calcitriol should be used with appropriate vigilance to
Metabolic acidosis also can contribute to renal osteodys-
prevent the development of an elevated calcium-phos-
trophy by stimulating osteoclastic activity or by causing
phorus product or hypercalcemia and oversuppressiondirect physicochemical dissolution of calcium [50]. Renal
of PTH. Doses of calcitriol lower than 0.25 to 0.5 mg/dayosteodystrophy, although rarely symptomatic, can cause
should provide safe but adequate suppression of PTHbone pain and an increased risk of fractures.
(goal PTH level, 100 to 300 pg/mL) [57, 58].The abnormalities that lead to renal osteodystrophy
occur early in renal insufficiency. Increased parathyroid Optimal control of cardiovascular complications
hormone (PTH) levels have been demonstrated when
The mortality rates due to cardiovascular disease arethe GFR falls below 60 to 80 mL/min, and levels continue
10 to 20 times higher among ESRD patients treated withto increase as renal function declines [51, 52]. Histologic
dialysis compared to the general population [39], and car-changes of renal osteodystrophy are manifest early in
diovascular disease accounts for nearly one-half of therenal insufficiency. Among patients with creatinine clear-
deaths among ESRD patients [3]. Morbidity due to cardio-ances of 20 to 59 mL/min, 87% of them had abnormal
vascular disease also is substantial. The Canadian Hemo-bone histology [53].
dialysis Morbidity Study reported a probability of hospitalThe skeletal changes as well as parathyroid hyperpla-
admission for nonfatal myocardial infarction (MI), angina,sia are not easily reversed with currently available thera-
or pulmonary edema among incident patients of 8% topies. Thus, early interventions to prevent secondary hy-
perparathyroidism and control metabolic acidosis are 10% per year [30], and in the Hemodialysis (HEMO)
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Table 2. Prevalence of cardiovascular disease among patients beginning renal replacement therapy a
ESRD Registry studies Cohort study
USRDSb[35] USRDSc[2] CORRd[62] ANZDATAe[63] Foley[41]
Year 1986–87 1996 1988–1996 1994–1997 1982–1991
Number of patients Population 3,399 3,468 24,497 5602 433
Coronary artery disease All 40.8% 36% (PD)f 37.2% 14.1%
Myocardial infarction 42% (HD)
Diabetic ,45 years 9.2%
Diabetic .45 years 24.0%
Non-diabetic ,45 years 2.2%
Non-diabetic .45 years 19.2%
Angina All 18.8%
Congestive heart failure All 41.1% 31% (PD) 30.8%
40% (HD)
Left-ventricular hypertrophy All 30.9% 18% (PD) 74.0%
22% (HD)
Cardiomegaly All 38.1%
a Table modified from Ref. 64
b USRDS[35], United States Renal Data System (USRDS) Case Mix-Severity Study
c USRDS[2], Dialysis Morbidity and Mortality Study Wave 2
d CORR[62], Canadian Organ Replacement Register
e ANZDATA[63], Australia and New Zealand Dialysis and Transplant Registry
f PD, peritoneal dialysis; HD, hemodialysis
Study, approximately one-third of first hospitalizations state (anemia, arteriovenous fistula, hypervolemia, hy-
perparathyroidism, and malnutrition) contribute to thewere related to cardiovascular complications [39].
Clinically apparent cardiovascular disease at onset of risk for cardiovascular disease among patients with CRF
[68]. Other non-traditional risk factors—elevated homo-RRT is a strong predictor of subsequent cardiac morbid-
ity and mortality. Patients with CHF at initiation of RRT cysteine, triglyceride, and Lp(a) levels—have a less well-
defined role in the pathogenesis of cardiovascular diseasehave a higher likelihood of subsequent episodes of CHF
compared to patients initially free of CHF, and the former [68, 69].
In summary, patients with CRF constitute a high-riskalso are at increased risk of all-cause mortality [35, 59].
Abnormalities in left-ventricular geometry on echocardi- group for cardiovascular morbidity and mortality. Con-
sequently, aggressive risk factor modification in the pre-ogram at initiation of RRT also are strong predictors
of subsequent cardiac morbidity and mortality among ESRD stage could reduce the prevalence of cardiovascu-
lar disease among patients reaching ESRD and couldESRD patients [18, 60].
Cardiovascular disease begins early in the course of improve outcomes among ESRD patients. The National
Kidney Foundation Task Force on Cardiovascular Dis-CRF and is present at the onset of dialysis in a substantial
fraction of patients (Table 2). The prevalence of echocar- ease recently published recommendations regarding car-
diovascular risk interventions in patients with CRF anddiographic evidence of LVH appears to be directly re-
lated to the severity of CRF. Among patients with creati- ESRD; these are summarized in Table 3 [70].
nine clearances less than 25 to 30 mL/min, LVH has
Adequate preparation for renal replacement therapybeen reported to be present in 38% to 45% of patients,
compared to a prevalence of 16% to 31% among patients Modality selection. Patient noncompliance with the
dialysis prescription is common in the U.S. and contrib-with creatinine clearances above that level [40, 61].
Traditional risk factors for cardiovascular disease— utes to suboptimal dialysis delivery [2]. Education and
informed choice of dialysis modality likely will enhanceolder age, male gender, diabetes mellitus, family history,
smoking, high blood pressure, LVH, high total choles- patient compliance, reduce the need for subsequent
modality changes, and facilitate the patient’s continuedterol levels, low high-density lipoprotein (HDL) levels,
physical inactivity, and menopause [65]—are common participation in the work force.
An informed decision on dialysis modality made underamong patients with CRF. Diabetes mellitus is the most
common cause of ESRD in the U.S., accounting for 42% non-emergency circumstances reduces the likelihood of
a subsequent change in dialysis modality. This processof new cases in 1996 [3]. At the onset of RRT, 75% to
100% of patients have hypertension [66]. Furthermore, is generally facilitated by early referral to the nephrolo-
gist [32, 71]. Patients referred to the nephrologist foreven among treated patients, blood pressure control is
often suboptimal [67]. Lipid abnormalities also are com- pre-ESRD care also are more likely to select peritoneal
dialysis compared to patients referred late [2]. Othermon, particularly among patients with nephrotic syn-
drome [68]. In addition, factors specific to the uremic important determinants of modality selection include fi-
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Table 3. Primary and secondary prevention of cardiovascular disease (CVD) in chronic renal failurea
Risk factor Rationale/target Intervention
Hypertension Volume control (“dry weight”) Salt restriction
Blood pressure control goals Diuretics
,125/75 mm Hg in patients with proteinuria Antihypertensive agents (ACE inhibitors are suggested)
,130/85 mm Hg in patients without proteinuria
Hyperlipidemia LDL #100 mg/dL Diet
HMG CoA reductase inhibitors (“statins”)
Hyperglycemia Normal or nearly normal blood glucose levels Diet
Oral agents
Insulin
Tobacco use Discontinue use Counseling
Nicotine replacement therapy
Physical activity Moderate physical activity (30 minutes per day, Regular exercise program
most days of the week)
Menopause Relationship between menopause and CVD in CRF Hormone replacement therapy
is poorly understood
Individual decision-making recommended
Homocysteine Effect of dietary fortification with folic acid on B vitamins (folic acid, B6, B12)
homocysteine levels, and the effect of lowering
homocysteine on cardiac risk are unknown
Thrombogenic factors Decreased platelet function and elevated procoagu- Aspirin (75–325 mg/day) is reasonable, but can worsen
lant activity platelet function
Revascularization Relief of ischemia, especially in high-risk patients CABG, PTCA (with stent)
LVH Hypertension and anemia are associated with the Diuretics and antihypertensive agents
development of LVH. Treatment of each con- Erythropoietin
dition causes regression of LVH, but the effect
of clinical cardiac events is yet unknown
Blood pressure target as above
Hematocrit target of 33%–36% as recommended
by the NKF-DOQIe
Screening
Stress tests Insufficient evidence to recommend routine stress Stress tests to detect inducible ischemia
tests. Pre-operative screening for non-cardiac
surgery and renal transplantation in high-risk
patients
Echocardiography Insufficient evidence to recommend for or against Echocardiography to assess left-ventricular mass
routine echocardiography for detection of
LVH
a Abbreviations are: ACE, angiotensin-converting enzyme; LVH, left-ventricular hypertrophy; CVD, cardiovascular disease; CRF, chronic renal failure; CABG,
coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; NKF-DOQIe, National Kidney Foundation Dialysis Outcomes Quality
Initiative. Modified from the recommendations of the National Kidney Foundation Task Force on Cardiovascular Disease [70].
nancial and reimbursement policies, physician prefer- assess social aspects of RRT, including the patient’s mo-
ence, resource availability, and the social background bility, housing conditions (especially if home dialysis is
and cultural habits of the patient. chosen), family support, continuation of employment,
Pre-ESRD education and intervention can play an transportation to the dialysis unit, and financial issues.
important role in modality selection and ensuring contin- Dialysis access placement. Patients who select perito-
uation of employment. A significantly higher proportion neal dialysis should have placement of a cuffed perito-
of peritoneal dialysis patients, a greater proportion of neal dialysis catheter two to four weeks prior to the
whom are under the care of a nephrologist prior to anticipated need for dialysis to reduce the possibility of
ESRD, take the lead in selecting dialysis modality com- temporary hemodialysis [73]. Patients who select hemo-
pared to hemodialysis patients (Fig. 6) [2]. In a study of dialysis should have a functioning permanent vascular
an educational intervention program, participants who
access at the initiation of RRT. A native arteriovenousreceived pre-ESRD education were more than twice as
fistula (AVF) is the preferred type of permanent vascularlikely to continue employment after the start of dialysis
access. Patients with AVFs have fewer complicationsthan were non-participants [72].
related to infection and thrombosis, and possibly betterDiscussions regarding the impending need for RRT
survival rates compared to patients with arteriovenousand choice of modality should be initiated at least six
grafts (AVGs) [30, 73–76]. Percutaneous catheters havemonths prior to the anticipated start of RRT. The renal
the highest complication rates and also result in a lowerteam should assess the patient’s suitability for dialysis
delivered dose of dialysis [77, 78]. Elective outpatientand transplantation and provide realistic advice regard-
ing therapeutic options. A detailed evaluation should placement of a permanent dialysis access obviates the
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less morbidity and later mortality compared with pa-
tients who begin dialysis at more traditional low levels
of renal function (late start). Although evidence from
controlled clinical trials is lacking, several observations
support this hypothesis. First, early initiation of dialysis
protects against malnutrition during the pre-ESRD pe-
riod and might prevent the increased morbidity and early
mortality related to malnutrition among dialysis patients.
Second, patients in whom dialysis is begun at a lower
GFR than the optimal solute clearance levels for dialysis
patients might suffer the same increased morbidity and
earlier mortality as the dialysis patients with poor soluteFig. 6. Physician and patient roles in selection of dialysis modality.
Choice was made by: the patient ( ); medical team, (h); or a collabora- clearances [32, 81]. Third, suboptimal control of volume
tion of both (j). Based on data from 2400 patients in the Dialysis
overload as well as decreased clearance of phosphate,Morbidity and Mortality Study of the United States Renal Data
advanced glycation end products, b2-microglobulin, andSystem [2].
other uremic toxins can lead to increased complication
rates. Finally, uncontrolled clinical studies from Italy in
the mid-1970s and the U.S. in the late 1980s suggest
need for hospital admission for initiation of dialysis, and that the severity of certain uremic complications and
reduces patient discomfort and cost [79]. mortality and hospitalization rates correlate inversely
Several recent studies have documented that fewer with residual renal function at the initiation of dialysis
than one-half of patients beginning dialysis in the U.S. [81–83].
have a permanent vascular access in place for their first Limited data are available regarding the level of resid-
treatment [2, 80]. In addition, despite the recognized ual renal function at initiation of RRT in the U.S. Most
superiority of AVF, there has been a trend towards more reports are based on levels of serum creatinine and/or
frequent placement of AVGs in the past decade, and estimated creatinine clearance and are limited to selected
more than 50% of patients required the use of a tempo- populations. In the MDRD study, GFR was measured
rary (uncuffed) catheter within the first 60 days of hemo- using iothalamate clearance in 94 patients who reached
dialysis [2]. There are several possible explanations for ESRD during the study period. The mean GFR at ini-
the popularity of AVGs. These include: (1) ease of place- tiation of dialysis was 9.0 mL/min/1.73 m2 [23]. In the
ment in numerous anatomic locations; (2) late referral CANUSA study, the mean average of renal creatinine
to a nephrologist, which precludes planned placement and urea clearance at initiation of dialysis was 3.8 mL/
of an AVF; and (3) preferences and technical skills of min [84]. There has been a steady trend in the U.S.
access surgeons. The fact that many patients do not recall toward beginning dialysis at lower levels of serum creati-
receiving instructions to “save” an arm for hemodialysis nine. In the late 1970s, the mean serum creatinine at the
access is further evidence of suboptimal planning for start of dialysis was 14.5 mg/dL [85]; in the 1980s, the
permanent vascular access in the U.S. [2]. mean serum creatinine concentration was 11.7 mg/dL
Education regarding vascular access should begin [86]. In contrast, the mean serum creatinine was 9.0 mg/
when the serum creatinine exceeds 3 mg/dL [73]. Patients dL in 1993 and 8.5 mg/dL in 1995 to 1997 [32]. We
and staff should be instructed to avoid phlebotomies recently examined GFR levels immediately prior to initi-
and intravenous lines in the cephalic veins as well as ation of chronic dialysis among patients who began dial-
subclavian vein cannulation. The DOQI guidelines rec- ysis between 1995 and 1997. Glomerular filtration rate
ommend placement of an AVF when the serum creati- was predicted by a formula derived from the MDRD
nine exceeds 4 mg/dL, creatinine clearance falls below study [87]. The mean (SD) predicted GFR was 7.1 mL/
25 mL/min, or ESRD is anticipated within one year. A min/1.73 m2 (SD 3.1) with a range from 1 to 42 mL/min/
maturation time of at least three months is recommended 1.73 m2. The proportion of patients with predicted GFR
[73]. Only patients who are not candidates for an AVF .10, 5 to 10, and ,5 mL/min/1.73 m2 was 14%, 63%,
or in whom an attempt has failed should have placement and 23%, respectively. The mean predicted GFR was
of an AVG, and these grafts ideally should not be used significantly lower among younger patients, women, Af-
for one month after surgery. rican-Americans, patients with higher body weight, pa-
Timing of initiation of dialysis. The rationale for tients with ESRD due to diseases other than diabetes,
timely initiation of RRT in patients with CRF has re- uninsured patients, patients who were employed, home-
cently been reviewed [32]. Several investigators have makers, students, and patients selecting hemodialysis
argued that patients who begin dialysis at relatively [88].
The Peritoneal Dialysis Adequacy Work Group ofhigher levels of residual renal function (early start) have
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the DOQI recommends initiation of dialysis when the the nephrologist would assume complete responsibility
for care.weekly renal Kt/Vurea decreases to below 2.0, unless all
Dr. Madias: I found the evidence you presented aboutthree of the following criteria are fulfilled: (1) stable
grossly suboptimal clinical practice at prominent medicalor increased edema-free body weight, (2) normalized
institutions very disturbing and suspect that the situationprotein-equivalent of total nitrogen appearance greater
is likely worse at institutions of lesser prominence. Whatthan 0.8 g/kg/day, and (3) absence of clinical symptoms
strategies can be used to improve this situation?and signs attributable to uremia [9]. Potential problems
Dr. Pereira: Yes, the level of care is quite worrisome.related to earlier initiation of hemodialysis include hemo-
Several recent reports have shown that pre-ESRD caredynamic instability, vascular-access-related infections,
at some inner-city hospitals is even worse than the datapotential adverse effects on longevity of the vascular
presented here suggest. What needs to be done? Someaccess, and faster decline in residual GFR. Concerns
organizations such as the National Kidney Foundationregarding earlier initiation of peritoneal dialysis include
have put together an Early Intervention and Preventionmorbidity associated with peritonitis and potential ad-
Task Force, which includes representatives of the targetverse effects on peritoneal membrane longevity. Finally,
physician groups, to develop a curriculum for primarythe economic consequences of earlier initiation of RRT
care physicians and family practitioners. This approachare a major concern in an era of rising health care costs.
is likely to become a necessity not just for nephrology,
but also for every other specialty, beginning at the medi-
QUESTIONS AND ANSWERS cal school level and extending to residency programs.
Dr. John T. Harrington (Dean, Tufts UniversityDr. Nicolaos E. Madias (Chief, Division of Nephrol-
School of Medicine, Boston): Brian, thank you for aogy, New England Medical Center, Boston, Massachu-
superb review. My question relates to the issue of timelysetts): Thank you, Brian, for this wonderful presentation.
initiation of dialysis. One can’t disagree with the notionYou spoke eloquently about the anticipated benefits to
that there should be timely initiation of dialysis. My fear,patients from early referral to nephrologists. Can you
however, is that we’re now being pushed into startingreflect a bit more on the overall impact of early referral
dialysis earlier than needed. If we start dialysis sixon the health care system in terms of cost and staffing?
months sooner, and patients live longer on dialysis byDr. Pereira: You bring up a very important issue,
six months, then we are faced with the problem of “lead-which is one of the reasons why this debate continues.
time bias,” and not a true benefit in terms of mortality.Certainly, referral to the nephrologist is likely to increase
All we’ve done is increase the cost to the system. Howcost over the pre-ESRD phase because of the use of
do you respond to this question?more advanced diagnostic and therapeutic interventions.
Dr. Pereira: John, that is a valid point. The same issueHowever, the incremental resources used over the pre-
arose in the breast and prostate cancer literature. If aESRD phase could be counterbalanced by: (1) prolonga-
condition is diagnosed earlier and the patient lives longer
tion of the pre-ESRD phase, with a resultant deferral of
from the time of diagnosis, lead-time bias must be consid-
dialysis with its cost of $60,000 per year and (2) lower ered. There is no water-tight way of dealing with lead-
first year (and potentially later) cost of ESRD due to time bias. One mechanism might be to adjust any analy-
better preparation for dialysis and less morbidity. If pa- ses of effects of early initiation of dialysis for the esti-
tients were to live significantly longer because of these mated duration of time the patient would have remained
interventions, the total cost would increase, but that is off dialysis. This interval could be predicted using an
a societal issue and one that arises with any intervention estimated rate of decline of renal function. The estimate
aimed at keeping patients alive and healthy. Unfortu- derived from the MDRD study is a rate of decrease of
nately, rigorous economic analyses are not available. GFR of 4 mL/min/year, and is assumed to be constant
The issue of who is going to look after these patients [11]. Lead-time bias is a serious concern that deserves
when the number of available nephrologists is limited is careful attention.
a major concern. I don’t believe that we have enough Dr. Harrington: You’ve presented many correlations
nephrologists to care for the patients who likely will of individual variables with outcomes, particularly serum
flood the system as the benefits of early referral become albumin. Could multivariate analyses of several factors
clear. A possible strategy is for nephrologists to develop tell us when we should start dialysis with a degree of
a partnership with primary care physicians and provide validity stronger than analyses of individual factors?
a complete set of recommended medical interventions. Dr. Pereira: No data are available that would allow
Initially, the nephrologist would develop an individual- us to make a prediction regarding who needs to start on
ized management plan. Thereafter the patient would be dialysis. Again, it comes back to the issue of lead-time
seen by the nephrologist approximately once yearly. bias. We have yet to prove that if a patient starts dialysis
when the GFR is 12 mL/min versus a GFR of 8 mL/min,When the serum creatinine level reached 4 mg/dL or so,
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the survival advantage will be more than the one year and health policy. First, who should take care of patients
with chronic renal insufficiency? What can we learnof “lead time,” assuming a rate of decline of 4 mL/min
per year. If by starting with a GFR of 12 mL/min versus about costs and outcomes from our colleagues in other
specialties, such as cardiology or diabetes? Second, I’m8 mL/min, survival is increased by significantly more
than one year, then it would seem worthwhile. If you’re afraid we might be naı¨ve to think that we can avoid the
costs that occur at the time of initiation of dialysis bybuying only the same one year or less, then it’s not worth
it to the patient, and the process actually might result in starting it earlier. It simply might be expensive to begin
dialysis with temporary access. Of course it would begreater societal cost. This issue needs to be fully resolved
before widespread recommendations can be made. desirable to avoid temporary access and hospitalization
for dialysis initiation. But in many cases, the onset ofDr. Ronald D. Perrone (Division of Nephrology,
New England Medical Center): Can you dissect out the renal failure is associated with an episode of illness that
requires hospitalization.components of cost in the first months following the
initiation of dialysis? My hunch is that the increased Dr. Pereira: Andy, your analogy to the cardiac patient
population is logical, but a myocardial infarction cannotcosts during this period are related to access issues.
Dr. Pereira: I suspect you are absolutely correct. We be predicted, and it is an acute event. At the New Eng-
land Medical Center, only 12% of patients who startedare in the process of ascertaining the cost of inpatient
and outpatient access procedures as well as hospitaliza- RRT developed ESRD following irreversible acute renal
failure. A typical example of this is the patient who hastions and total hospital days attributable to access, in-
cluding access procedures performed during hospitaliza- diabetes and chest pain and who undergoes catheteriza-
tion, which results in irreversible renal failure. However,tions for another reason. Our preliminary analyses do
reveal that access-related hospitalizations are the major in the vast majority of patients, initiation of dialysis can
be planned. Among these patients in whom renal re-cause of resource utilization in the first six months of
dialysis. placement therapy could have been planned, the cost of
initiating dialysis probably could be diminished by earlyDr. Perrone: Could you share your thoughts about
prospective clinical trials in which dialysis would be initi- nephrology referral, and by timely vascular access place-
ment and initiation of dialysis. I strongly believe thatated at different levels of GFR and all else would be
equal, that is, access is in place, erythropoietin is appro- planned initiation would decrease the excessive costs
incurred in the first six months of dialysis.priately used, etc.?
Dr. Pereira: I am doubtful that there ever will be a The first issue you raised is much harder to answer—
who should take care of patients with chronic renal fail-prospective trial. Years ago, when Bloembergen and col-
leagues showed that early mortality was higher in perito- ure? There are conflicting results on outcomes compar-
ing care between specialists and non-specialists. In theneal dialysis patients [89], a prospective “randomized”
trial was initiated. However, it was noted that when the area of cardiology, one study showed that the one-year
mortality rate was 12% lower among patients with acuteoptions of dialytic therapy were presented by a person
committed to peritoneal dialysis, a larger proportion of myocardial infarction who were cared for by cardiolo-
gists compared to patients cared for by generalists [90].patients chose peritoneal dialysis. Conversely, in areas
where people are strongly opposed to peritoneal dialysis, In contrast, in another study of patients with unstable
angina, rates of death or myocardial infarction were simi-the opposite was seen. Thus, the randomization process
failed, and I believe that biases regarding the correct level lar among patients cared for by non-cardiologists or
cardiologists [91]. In this latter study, cost of care wasof GFR for initiation of dialysis would lead to a similar
outcome. Dr. Levey might have an opinion on this. $2,000 lower among patients cared for by non-cardiolo-
gists (a non-significant difference) and the length of hos-Dr. Andrew S. Levey (Division of Nephrology, New
England Medical Center): I agree that this would be a pital stay did not differ.
Dr. Andrew J. King (Division of Nephrology, Newhard clinical trial to do. Patients would be eligible for
entry only when their level of renal function was within England Medical Center): You alluded to the increasing
use of ACE inhibitors before ESRD to control blooda certain range, assuming the level of renal function
could be estimated accurately and conveniently. During pressure and to retard the progression of renal disease.
Do you have any information regarding the use of otherthat time, they would have to be randomized into the
study, and early intervention would have to begin before known preventive measures for cardiovascular disease,
in particular, the use of aspirin or cholesterol-loweringthe renal function fell below the threshold level for inter-
vention in the control group. I would expect a large agents, in the pre-ESRD patient population?
Dr. Pereira: Little data are available in the ESRDnumber of “drop-ins” and “drop-outs” from the early
intervention group, which would minimize the difference population regarding these other interventions, and we
have even less data in pre-ESRD patients. The Nationalin outcomes between the randomized groups.
I wanted to ask you two questions about economics Kidney Foundation Task Force has published recom-
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mendations regarding the treatment of cardiovascular it appeared in that study that the lower the level of
disease among patients with chronic renal insufficiency renal function, the more amino acid abnormalities were
and ESRD (dialysis and transplantation), generally ex- present.
trapolating data from patients without renal failure [70]. Dr. Klemens B. Meyer (Division of Nephrology, New
The recommendation for management of hyperlipidemia England Medical Center): As a practicing nephrologist,
is that physicians follow the National Cholesterol Educa- I am a bit confused. Only a few years ago the Federal
tion Program Adult Treatment Panel guidelines for the government accused nephrologists of starting patients
general population. These include obtaining a fasting lipid on dialysis too early. I still regularly sign government
profile on patients with HDL cholesterol #35 mg/dL or forms explaining why we started dialysis in a patient with
total cholesterol $200 mg/dL. The target is an LDL an estimated GFR exceeding 10 mL/min. Now you are
cholesterol level of #100 mg/dL, to be achieved with suggesting that dialysis be started earlier. Could you
dietary or drug intervention, depending on initial level. comment on this reversal?
Given the increased risk of platelet dysfunction with Dr. Pereira: I had the opportunity to be involved in
lower levels of renal function, the use of aspirin in low a case a few years ago in which it was alleged that, to gain
doses is recommended only for patients with mild renal financially from the system, unscrupulous nephrologists
insufficiency or those with a high risk for cardiovascular were starting patients on dialysis too early. The USRDS,
disease. We don’t know the impact of these interventions which was asked to analyze the centers believed to be
and outcomes in patients with renal failure. exploiting the system, found that patients who were “be-
Dr. Madias: You referred to malnutrition in uremia ing started on dialysis earlier” (and who had been denied
but, as you know, heart disease itself is a cause of malnu- eligibility by the Medical Advisory Board of the regional
trition. Could you please comment on the association ESRD network) had a mortality rate that was threefold
between malnutrition and cardiac and renal disease? higher than those who had been approved by the Medical
Dr. Pereira: The link between inflammation in ure- Advisory Board. An example is the 90-year-old lady who
mia, malnutrition, and cardiac disease has been an area weighs 40 kilograms and has intractable heart failure but
of focus in our laboratory. We among others strongly a serum creatinine of only 2.5 to 3 mg/dL. The Medical
believe that these factors are interrelated, with inflam- Advisory Board would not be able to decide whether
mation having a strong effect on heart disease and mal- this patient should be on dialysis. The truth of the matter
nutrition, and these latter two factors having an effect is that there was no exploitation of the system. Such
on each other. The possible cause of inflammation in the patients were justifiably on dialysis irrespective of their
pre-ESRD stage is not defined. In the ESRD setting, we serum creatinine levels.
have more information available; dialyzer membranes,
Dr. Meyer: This leads to another observation: the
contaminants in the dialysate, and dialysis-related in-
definition of ESRD is becoming less clear. You implicitlyterventions, such as the use of intravenous iron, could
raise questions about how one defines “end-stage” andtrigger inflammation. Some of us believe that pro-
whether one should even wait until the “end stage” toinflammatory cytokines might be important mediators
initiate dialysis. Also, there’s the question of whetherof inflammation, with the C-reactive protein being simply
we only initiate chronic dialysis for end-stage renal fail-a marker of the inflammatory state. This “inflammatory
ure. Isn’t it helpful to think of chronic dialysis as a treat-state” might suppress albumin gene expression in the
ment for a certain level of renal function given the pa-liver and lead to hypoalbuminemia. Inflammation also
tient’s cardiac function?can trigger inflammatory and endothelial cell reactions
Dr. Pereira: I agree with you. Many times patientsand can induce atherogenesis in experimental models.
have not reached ESRD. We have no firm definition ofHeart failure itself can reduce appetite, thus contributing
ESRD. We arbitrarily define it as reaching the point atto malnutrition. The role of inflammation in uremia is
which one requires renal replacement therapy. Whenan area of active investigation.
this end-point is reached is subjective, and it dependsDr. Madias: Is the protein malnutrition incurred in
on the clinical characteristics of the patient. For example,uremia sufficient to cause depletion of L-arginine, the
a patient with heart failure and a GFR of 22 mL/minsubstrate of nitric oxide, with resultant cardiovascular
who requires dialysis would be considered to have ESRDconsequences?
because RRT would be necessary to manage severeDr. Pereira: I am not certain about this. Perhaps Dr.
edema, not because of a particular level of renal function.Levey has the answer.
Dr. Meyer: One final question. What about the pa-Dr. Levey: l-arginine levels were nearly normal in the
tients who shouldn’t receive or be subjected to renalMDRD study, except among patients with the lowest
replacement therapy? With all the emphasis on startinglevel of renal function, that is, those with a creatinine
early, is anyone thinking about counseling patients andclearance below 15 mL/min/1.73 m2, who have l-arginine
levels approximately 20% below normal [92]. In general, families regarding conservative options?
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Dr. Pereira: Are you talking about patients who on dialysis, and there is less societal acceptance of non-
intervention.shouldn’t be on renal replacement therapy at all?
Dr. Meyer: That’s correct.
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